More Videos
- Genentech Regains "Title" As Best Biopharma Employer
- The Last Word--For Now--On Dendreon
- Barack Obama: Big Pharma's Million Dollar Man
- Roche Speaks My Language But Genentech Not So Much
- Could The Credit Crisis Help Pfizer?
- Biotech Bonanza For ImClone & Dendreon
- Dendreon, ImClone & Pfizer: Your Emails
- Lilly's "Secret" (About ImClone) Is Out--Or Is It?
- Oktoberfest For ImClone & Dendreon (Update On Mystery Bid)
- The Waiting Game Continues For Lilly & ImClone
- Bowyer: Mark To Market Still Lives (Unfortunately)
- Mad Mail: Why Not Shut the Market Down?
- Lightning Round OT: AFLAC, Valero and More
- Lightning Round: Chesapeake, Corning, J&J and More
- Cramer: What’s the Worst-Case Scenario?
- Game Plan: The Crash of '87 Scenario
- Cramer’s Double Secret Borrow-Binge Plan
- Your First Move For Monday October 13th
- History In The Making
- GM Held Talks With Ford Before Turning to Chrysler
- Markets to Fall 20% More at Most: IMF Economist
- G.M. and Chrysler Explore Merger
- Stock Market Crisis: Nation's Mayors Sound Off
- US Banks Keep Pressure on SEC to Deal With Shorts
- Financial Crisis Has Inflationary And Deflationary Potential
- What the Pros Say: Swap Jitters, Bottom Searches
- Viacom Warns of Third-Quarter Profit Shortfall
- US Consumers Lose Faith in Fed Due to Crisis
Text Size 
 |
AP Bobby Murcer as New York Yankees broadcaster |
] announced it's doing a deal worth up to $440 million over time with a baby biotech called Avant Immunotherapeutics [AVAN
Loading...
()
] .It's a partnership on an experimental brain cancer treatment that Yankee center fielder and announcer Bobby Murcer tried in one of the clinical trials.
He's still recovering from the recent discovery of scar tissue--reportedly not a cancer recurrence--that required a biopsy and follow-up treatment that zapped his energy. So much so, that he hasn't been able to work in the broadcast booth this season.
The drug is another one of those therapeutic cancer vaccines that I've blogged about a lot in relation to Dendreon [DNDN
Loading...
()
]. But the Avant drug, which it got in a recent deal with the privately held Celldex Therapeutics, is for the most common and aggressive form of brain cancer.
Dendreon Posts |
Sadly, there really haven't been any medical breakthroughs for it in the past few decades and the prognosis is never very good.
Many biotech and drug companies are working on treatments. For example, Genentech [DNA
Loading...
()
] just announced it plans to file by the end of this year for Food and Drug Administration approval of its cancer drug Avastin for use on brain tumors.
This latest PFE deal is chump change for the company which is absolutely loaded with cash. But it's a potential game-changer for a tiny biotech like Avant. Pfizer's giving AVAN $40 million cash money up front, buying $10 million worth of stock, is on the hook for milestone payments over time of more than $390 million and double-digit royalties on sales if this drug or similar ones from Avant ever gets to market--whether for brain tumors or possibly other tumor types.
So, it's a huge deal for Avant, but a relatively cheap bet for Pfizer which needs to swing at nearly every pitch. Investors are waiting for Pfizer to hit one out of the park.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes